Checkpoint Therapeutics’ (CKPT) “Buy” Rating Reiterated at D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT – Free Report) in a research note released on Monday,Benzinga reports. They currently have a $4.80 price target on the stock. A number of other research firms have also weighed in on CKPT. Lake Street Capital reissued a “hold” rating and issued […]
D. Boral Capital reaffirmed their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT – Free Report) in a research note released on Monday,Benzinga reports. They currently have a $4.80 price target on the stock. A number of other research firms have also weighed in on CKPT. Lake Street Capital reissued a “hold” rating and issued […]
